Predictive Oncology to Report First Quarter 2024 Financial Results on Wednesday, May 15, 2024
Predictive Oncology Inc. (NASDAQ: POAI) will report its financial results for the first quarter ended March 31, 2024 on Wednesday, May 15, 2024. The company, known for leveraging AI and machine learning in oncology drug discovery, will host a corporate update conference call and webcast at 8:30 a.m. ET.
- None.
- None.
Management to host conference call and webcast at 8:30am ET
PITTSBURGH, May 10, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the first quarter ended March 31, 2024 before the markets open on Wednesday, May 15, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET.
| Live Conference Call & Webcast: | ||
| Toll Free: | 877-407-3982 | |
| International: | 201-493-6780 | |
| Conference ID: | 13746389 | |
| Call me™: | here | |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1669074&tp_key=149e847466 | |
A replay of the webcast will be available in the Investors section of the Predictive Oncology website at https://investors.predictive-oncology.com/events-and-presentations.
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with
Contact:
Predictive Oncology Inc.
Theresa Ferguson, Senior Director of Marketing
Phone: (630) 566-2003
tferguson@predictive-oncology.com
Predictive Oncology Investor Relations
Tim McCarthy
LifeSci Advisors, LLC.
tim@lifesciadvisors.com
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
FAQ
When will Predictive Oncology report its first quarter 2024 financial results?
What is the stock symbol of Predictive Oncology?
What technology does Predictive Oncology leverage in drug discovery?
When will the corporate update conference call and webcast take place?
Where can I find a replay of the webcast?
